The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4953	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4954	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4955	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4956	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4957	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4958	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4959	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4960	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4961	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4962	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4963	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4964	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4965	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4966	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4967	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4968	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4969	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4970	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4971	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4972	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result40% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4973	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4974	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result5% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4975	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result44% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4976	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result35% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4977	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4978	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineLewis lung cancer cell line	Cell lineLLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result2% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4979	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC54BL/6 mice xenograft for A549 cell line (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1000 cubic mm compared to control 2200 cubic mm after 27 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4980	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismImmunocompetant mice xenograft for LLC	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 5000 cubic mm compared to control 10000 cubic mm after 15 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_5007	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result35% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5008	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result22% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5009	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5010	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result36% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5011	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result24% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5012	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5013	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result35% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5014	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result22% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5015	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine melanoma cell line	Cell lineB16	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result18% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5016	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result55% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5017	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result42% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5018	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5019	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5020	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result44% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5021	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5022	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5023	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result46% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5024	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5025	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result68% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5026	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result36% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5027	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result26% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5028	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result68% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5029	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5030	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5031	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result65% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5032	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result36% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5033	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result22% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5034	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5035	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5036	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5037	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result52% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5038	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result38% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5039	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5040	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result51% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5041	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result38% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5042	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine hepatoma cell line	Cell lineHepal-6	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result21% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5043	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5044	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5045	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5046	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5047	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5048	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5049	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5050	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5051	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma cell line	Cell lineMDA-MB-231	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5052	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5053	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5054	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5055	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5056	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5057	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result22% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5058	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5059	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5060	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineSMMC7721	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result21% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5061	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC56BL/6 mice xenograft for SMMC-7721 (1.0E+6 cells )	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultProlongs the survival time	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5062	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC56BL/6 mice xenograft for SMMC-7721 (1.0E+6 cells )	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultProlongs the survival time	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5092	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5093	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5094	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5095	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5096	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5097	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5098	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5099	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineHS294T	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5100	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5101	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5102	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5103	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5104	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result80% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5105	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5106	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5107	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineA2058	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058